External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Challenging Quarter: Dhanuka reported a 9% YoY decline in revenue during Q2FY26, missing estimates due to erratic and uneven rainfall across key growing regions.</li><li>Adverse weather conditions resulted in crop damage and limited agrochemical usage.</li><li>The herbicide portfolio was particularly impacted, with subdued demand from major crops such as soybean, groundnut, and cotton, as irregular precipitation restricted application opportunities. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Challenging Quarter: Dhanuka reported a 9% YoY decline in revenue during Q2FY26, missing estimates due to erratic and uneven rainfall across key growing regions.Adverse weather conditions resulted in crop damage and limited agrochemical usage.The herbicide portfolio was particularly impacted, with subdued demand from major crops such as soybean, groundnut, and cotton, as irregular precipitation restricted application opportunities. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dhanuka Agritech Ltd - Looking Beyond the Storm, Seeding Long-Term Growth

<ul><li>Modest Start to FY26; Signs of Recovery in Q2: Dhanuka commenced FY26 on a cautious note, posting a 7% YoY revenue growth in Q1, driven by 5% growth in volumes and a 7% improvement in realisations.</li><li>The delayed and uneven onset of the southwest monsoon impacted the timely sowing of kharif crops, leading to softer demand for agri-inputs, particularly herbicides.</li><li>Additionally, farmer sentiment remained conservative due to rainfall uncertainties and lower price realisations from the previous harvest. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Modest Start to FY26; Signs of Recovery in Q2: Dhanuka commenced FY26 on a cautious note, posting a 7% YoY revenue growth in Q1, driven by 5% growth in volumes and a 7% improvement in realisations.The delayed and uneven onset of the southwest monsoon impacted the timely sowing of kharif crops, leading to softer demand for agri-inputs, particularly herbicides.Additionally, farmer sentiment remained conservative due to rainfall uncertainties and lower price realisations from the previous harvest. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dhanuka Agritech Ltd - Weaker-Than-Expected Q1; Expecting to Recoup Growth in Q2

<ul><li>Revenue Growth Along With Margin Expansion: Dhanuka delivered impressive results this quarter, with a 20% YoY revenue growth driven by 19% volume growth and 20% value growth.</li><li>Operating margins expanded significantly to 24.8%, supported by a favourable product mix, strong sales performance, and the launch of new products.</li><li>The company’s ongoing investment in process research is showing promising outcomes, with several new products in the pipeline. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Revenue Growth Along With Margin Expansion: Dhanuka delivered impressive results this quarter, with a 20% YoY revenue growth driven by 19% volume growth and 20% value growth.Operating margins expanded significantly to 24.8%, supported by a favourable product mix, strong sales performance, and the launch of new products.The company’s ongoing investment in process research is showing promising outcomes, with several new products in the pipeline. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dhanuka Agritech Ltd - Performance Beat on All Fronts; Maintain BUY

<ul><li>New products continue to drive growth: During the quarter, the company experienced margin expansion on a YoY basis, primarily driven by a favorable product mix and new product introductions, strong sales, and liquidation of key products such as LaNevo and MYCORe Super.</li><li>Both these products, launched this year, have been well received by farmers across India.</li><li>Additionally, the company introduced a new 9(4) product, “Roxa” – Pyroxasulfone 85% WG, aimed at controlling weeds in wheat crops, which has garnered a positive market response. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

New products continue to drive growth: During the quarter, the company experienced margin expansion on a YoY basis, primarily driven by a favorable product mix and new product introductions, strong sales, and liquidation of key products such as LaNevo and MYCORe Super.Both these products, launched this year, have been well received by farmers across India.Additionally, the company introduced a new 9(4) product, “Roxa” – Pyroxasulfone 85% WG, aimed at controlling weeds in wheat crops, which has garnered a positive market response. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dhanuka Agritech Ltd - New Launches to Strengthen the Portfolio; Maintain BUY

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

<ul>
<li>Shivalik Rasayan, once focused on agrochemicals, has entered pharmaceuticals by acquiring Medicamen Biotech and securing USFDA approval for its new API plant at Dahej-II in 2024.</li>
<li>The company is transforming into a diversified chemicals and pharma player. Investments in R&amp;D, larger agrochemical capacity, and regulated pharma access open pathways for higher-margin and sustainable growth.</li>
<li>Despite past issues of underutilized plants, high costs, and delays, recent approvals and new facilities position Shivalik Rasayan for steadier performance and long-term growth if execution remains strong.</li>
</ul>


Shivalik Rasayan, once focused on agrochemicals, has entered pharmaceuticals by acquiring Medicamen Biotech and securing USFDA approval for its new API plant at Dahej-II in 2024.
The company is transforming into a diversified chemicals and pharma player. Investments in R&amp;D, larger agrochemical capacity, and regulated pharma access open pathways for higher-margin and sustainable growth.
Despite past issues of underutilized plants, high costs, and delays, recent approvals and new facilities position Shivalik Rasayan for steadier performance and long-term growth if execution remains strong.


The Beat Ideas: Shivalik Rasayan: Does USFDA Approval Marks a New Growth Chapter?

India

Dhanuka Agritech Ltd. manufactures insecticides, pesticides and other chemicals. The Company has a technical tie-up with M/s E.I. Dupont De Numours & Co., U.S.A. to formulate the product Methomyl 12.5L under brand name "Dunet".

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Dhanuka Agritech (DAGRI IN)

Dhanuka Agritech Ltd - Looking Beyond the Storm, Seeding Long-Term Growth

Challenging Quarter: Dhanuka reported a 9% YoY decline in revenue during Q2FY26, missing estimates due to erratic and uneven rainfall across key...

Axis Direct

Dhanuka Agritech Ltd - Weaker-Than-Expected Q1; Expecting to Recoup Growth in Q2

Dhanuka commenced FY26 on a cautious note, posting a 7% YoY revenue growth in Q1, driven by 5% growth in volumes and a 7% improvement in realisations.

Axis Direct

Dhanuka Agritech Ltd - Performance Beat on All Fronts; Maintain BUY

Revenue Growth Along With Margin Expansion: Dhanuka delivered impressive results this quarter, with a 20% YoY revenue growth driven by 19% volume...

Axis Direct

Dhanuka Agritech Ltd - New Launches to Strengthen the Portfolio; Maintain BUY

During the quarter, the company experienced margin expansion on a YoY basis, primarily driven by a favorable product mix and new product...

Axis Direct

The Beat Ideas: Shivalik Rasayan: Does USFDA Approval Marks a New Growth Chapter?

Shivalik Rasayan expands into pharmaceuticals with Medicamen Biotech acquisition and USFDA approval for new API plant, aiming for diversified...

Sudarshan Bhandari

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Dhanuka Agritech Ltd - Looking Beyond the Storm, Seeding Long-Term Growth

Challenging Quarter: Dhanuka reported a 9% YoY decline in revenue during Q2FY26, missing estimates due to erratic and uneven rainfall across key...

Axis Direct

Dhanuka Agritech Ltd - Weaker-Than-Expected Q1; Expecting to Recoup Growth in Q2

Dhanuka commenced FY26 on a cautious note, posting a 7% YoY revenue growth in Q1, driven by 5% growth in volumes and a 7% improvement in realisations.

Axis Direct

Dhanuka Agritech Ltd - Performance Beat on All Fronts; Maintain BUY

Revenue Growth Along With Margin Expansion: Dhanuka delivered impressive results this quarter, with a 20% YoY revenue growth driven by 19% volume...

Axis Direct

Dhanuka Agritech Ltd - New Launches to Strengthen the Portfolio; Maintain BUY

During the quarter, the company experienced margin expansion on a YoY basis, primarily driven by a favorable product mix and new product...

Axis Direct

The Beat Ideas: Shivalik Rasayan: Does USFDA Approval Marks a New Growth Chapter?

​Shivalik Rasayan expands into pharmaceuticals with Medicamen Biotech acquisition and USFDA approval for new API plant, aiming for diversified...

Sudarshan Bhandari

Shivalik Rasayan expands into pharmaceuticals with Medicamen Biotech acquisition and USFDA approval for new API plant, aiming for diversified...